Tapimmune Inc (TPIV) 1.1300 $TPIV
TapImmune, Inc. to Present at SeeThruEquity Microcap Conference
ACCESSWIRE - Thu Sep 04, 8:01AM CDT
Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City. The presentation is scheduled for 10:00AM ET.
TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference
ACCESSWIRE - Wed Sep 03, 9:42AM CDT
Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Wednesday, September 10th at 2:30 p.m. EDT in the Kennedy I Salon (4th floor) at the New York Palace Hotel in New York City.
SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million
ACCESSWIRE - Tue Aug 19, 7:51AM CDT
New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
TapImmune, Inc. Announces $2 Million Registered Direct Offering
Business Wire - Mon Aug 11, 11:21AM CDT
TapImmune, Inc. (the "Company"
, (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share.
TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
Business Wire - Thu Aug 07, 8:23AM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer. Folate receptor alpha is over a 100 fold elevated in 90% of ovarian cancer cells and is thus an excellent target for immunotherapy.
TapImmune Prevails in Legal Dispute with Michael Gardner
Business Wire - Thu Jul 24, 8:38AM CDT
TapImmune Inc. (OTCQB:TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.
New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer
ACCESSWIRE - Wed Jul 23, 7:06AM CDT
Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company's scientific advisory board.
SeeThruEquity Issues Company Note on TapImmune Highlighting Valuation as Compared with Peers
ACCESSWIRE - Tue Jul 01, 8:02AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on TapImmune Inc. (OTCQB: TPIV).
TapImmune elects Dr Keith Knutson as chair of its scientific advisory board
M2 - Fri Jun 13, 5:26AM CDT
Immunotherapy company TapImmune (Other OTC:TPIV) disclosed on Thursday the addition of Dr Keith Knutson, PhD as chair of its scientific advisory board.
TapImmune Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board
Business Wire - Thu Jun 12, 4:16PM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company's scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St. Lucie, FL (VGTI Florida). TapImmune has licensed cancer vaccine technologies originating from Dr. Knutson's former laboratory at the Mayo Clinic, which are currently completing Phase I clinical trials in breast and ovarian cancer. The start of Phase II clinical studies in planned for the end of 2014. Glynn Wilson, TapImmune CEO said, "We are delighted to have someone with Keith's vision and scientific knowledge to lead our scientific advisory board. As a recognized leader in immunotherapy of breast and ovarian cancer, it is a great to have his input into the Company's clinical development programs. Under Dr. Knutson's leadership, TapImmune will continue to build a world-class scientific advisory board to review and advance all scientific programs."
TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
ACCESSWIRE - Tue Feb 25, 8:42AM CST
SEATTLE, WA / Feb 25, 2014 / ACCESSWIRE / TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
Janssen Announces New Group Targeting Unmet Global Health Needs
PR Newswire - Wed Jan 22, 7:15AM CST
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs. Janssen GPH will align the company's groundbreaking science and innovative access models under a single entity to drive better health outcomes, improve quality of life for patients, and sustainably advance health for people all over the world.
TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations
ACCESSWIRE - Wed Jun 26, 10:31AM CDT
Seattle, WA, June 26, 2013 (eTeligis via ACCESSWIRE) -- TapImmune (OTCQB: TPIV)
TapImmune Inc names Sherry Grisewood to board
M2 - Thu Mar 21, 9:37AM CDT
Vaccine company TapImmune Inc (OTC BB:TPIV) revealed on Wednesday the appointment of Sherry Grisewood, CFA to the board of directors.
TapImmune Announces the Appointment of Sherry Grisewood to the Board of Directors
PR Newswire - Wed Mar 20, 8:00AM CDT
TapImmune Inc. (OTCQB: TPIV) has pleasure in announcing the appointment of Sherry Grisewood, CFA to the Board of Directors. She has over 25 years securities industry experience in a range of investment banking, advisory and research-related activities. She currently has a senior banking and banking analytical role at Dawson James Securities. Prior to joining Dawson James, she was Managing Director, Lifesciences and Technology Banking for Tripoint Global Equities. Sherry served as Senior Life Sciences Banker at Jesup & Lamont Securities Corp. and as an independent strategic advisor and consultant for several investment banks over the prior 12 year period. She has participated in over 50 transaction-related projects worldwide involving initial public offerings, secondary offerings, PIPE's, private equity, M&A and licensing transactions in the life sciences sector. Prior to consulting for investment banks, Sherry served as Director of Research for several mid-tier brokerage companies and a leading independent
TapImmune Inc. to Present at the Florida Road Show Conference on March 14, 2013
PR Newswire - Wed Mar 13, 8:00AM CDT
TapImmune Inc. ("TapImmune" or the "Company" (OTCQB: TPIV), an immunotherapy company focused on the development of novel peptide and gene-based vaccine technologies, announced today that the Company will present at the Florida Road Show Conference in Boca Raton, Florida on Thursday, March 14, 2013. This conference, hosted by Corporate Roadshow and Undiscovered Equities, will feature presentations by CEOs and CFOs of promising emerging growth companies to an invited audience of investment bankers, analysts, hedge-fund managers, top brokers and accredited investors.
OTC Signal Daily Stock Watch
WorldStockWire - Tue Jan 22, 11:28PM CST
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu Antigens
PR Newswire - Wed Jan 09, 8:00AM CST
TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The proprietary HER2/neu Class II antigens, discovered by Keith Knutson Ph.D. and colleagues at Mayo Clinic, show high affinity binding to human MHC proteins for ~84% of the population making it potentially applicable to a broad spectrum of HER2/neu patients compared to other approaches. The Phase I trial is being carried out in breast cancer patients who finished standard Herceptin®-based therapy and are at risk of disease recurrence. The primary endpoints of the study are safety and immunogenicity. Details of the Phase I trial can be found at http://clinicaltrials.gov. TapImmune is sponsoring the Phase I study and has an Exclusive Option to Li
TapImmune, Inc. to Present at SeeThruEquity Microcap Conference
ACCESSWIRE - Thu Sep 04, 8:01AM CDT
Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City. The presentation is scheduled for 10:00AM ET.
TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference
ACCESSWIRE - Wed Sep 03, 9:42AM CDT
Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Wednesday, September 10th at 2:30 p.m. EDT in the Kennedy I Salon (4th floor) at the New York Palace Hotel in New York City.
SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million
ACCESSWIRE - Tue Aug 19, 7:51AM CDT
New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
TapImmune, Inc. Announces $2 Million Registered Direct Offering
Business Wire - Mon Aug 11, 11:21AM CDT
TapImmune, Inc. (the "Company"
, (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share. TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
Business Wire - Thu Aug 07, 8:23AM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer. Folate receptor alpha is over a 100 fold elevated in 90% of ovarian cancer cells and is thus an excellent target for immunotherapy.
TapImmune Prevails in Legal Dispute with Michael Gardner
Business Wire - Thu Jul 24, 8:38AM CDT
TapImmune Inc. (OTCQB:TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.
New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer
ACCESSWIRE - Wed Jul 23, 7:06AM CDT
Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company's scientific advisory board.
SeeThruEquity Issues Company Note on TapImmune Highlighting Valuation as Compared with Peers
ACCESSWIRE - Tue Jul 01, 8:02AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on TapImmune Inc. (OTCQB: TPIV).
TapImmune elects Dr Keith Knutson as chair of its scientific advisory board
M2 - Fri Jun 13, 5:26AM CDT
Immunotherapy company TapImmune (Other OTC:TPIV) disclosed on Thursday the addition of Dr Keith Knutson, PhD as chair of its scientific advisory board.
TapImmune Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board
Business Wire - Thu Jun 12, 4:16PM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company's scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St. Lucie, FL (VGTI Florida). TapImmune has licensed cancer vaccine technologies originating from Dr. Knutson's former laboratory at the Mayo Clinic, which are currently completing Phase I clinical trials in breast and ovarian cancer. The start of Phase II clinical studies in planned for the end of 2014. Glynn Wilson, TapImmune CEO said, "We are delighted to have someone with Keith's vision and scientific knowledge to lead our scientific advisory board. As a recognized leader in immunotherapy of breast and ovarian cancer, it is a great to have his input into the Company's clinical development programs. Under Dr. Knutson's leadership, TapImmune will continue to build a world-class scientific advisory board to review and advance all scientific programs."
TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
ACCESSWIRE - Tue Feb 25, 8:42AM CST
SEATTLE, WA / Feb 25, 2014 / ACCESSWIRE / TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
Janssen Announces New Group Targeting Unmet Global Health Needs
PR Newswire - Wed Jan 22, 7:15AM CST
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs. Janssen GPH will align the company's groundbreaking science and innovative access models under a single entity to drive better health outcomes, improve quality of life for patients, and sustainably advance health for people all over the world.
TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations
ACCESSWIRE - Wed Jun 26, 10:31AM CDT
Seattle, WA, June 26, 2013 (eTeligis via ACCESSWIRE) -- TapImmune (OTCQB: TPIV)
TapImmune Inc names Sherry Grisewood to board
M2 - Thu Mar 21, 9:37AM CDT
Vaccine company TapImmune Inc (OTC BB:TPIV) revealed on Wednesday the appointment of Sherry Grisewood, CFA to the board of directors.
TapImmune Announces the Appointment of Sherry Grisewood to the Board of Directors
PR Newswire - Wed Mar 20, 8:00AM CDT
TapImmune Inc. (OTCQB: TPIV) has pleasure in announcing the appointment of Sherry Grisewood, CFA to the Board of Directors. She has over 25 years securities industry experience in a range of investment banking, advisory and research-related activities. She currently has a senior banking and banking analytical role at Dawson James Securities. Prior to joining Dawson James, she was Managing Director, Lifesciences and Technology Banking for Tripoint Global Equities. Sherry served as Senior Life Sciences Banker at Jesup & Lamont Securities Corp. and as an independent strategic advisor and consultant for several investment banks over the prior 12 year period. She has participated in over 50 transaction-related projects worldwide involving initial public offerings, secondary offerings, PIPE's, private equity, M&A and licensing transactions in the life sciences sector. Prior to consulting for investment banks, Sherry served as Director of Research for several mid-tier brokerage companies and a leading independent
TapImmune Inc. to Present at the Florida Road Show Conference on March 14, 2013
PR Newswire - Wed Mar 13, 8:00AM CDT
TapImmune Inc. ("TapImmune" or the "Company"
(OTCQB: TPIV), an immunotherapy company focused on the development of novel peptide and gene-based vaccine technologies, announced today that the Company will present at the Florida Road Show Conference in Boca Raton, Florida on Thursday, March 14, 2013. This conference, hosted by Corporate Roadshow and Undiscovered Equities, will feature presentations by CEOs and CFOs of promising emerging growth companies to an invited audience of investment bankers, analysts, hedge-fund managers, top brokers and accredited investors. OTC Signal Daily Stock Watch
WorldStockWire - Tue Jan 22, 11:28PM CST
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu Antigens
PR Newswire - Wed Jan 09, 8:00AM CST
TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The proprietary HER2/neu Class II antigens, discovered by Keith Knutson Ph.D. and colleagues at Mayo Clinic, show high affinity binding to human MHC proteins for ~84% of the population making it potentially applicable to a broad spectrum of HER2/neu patients compared to other approaches. The Phase I trial is being carried out in breast cancer patients who finished standard Herceptin®-based therapy and are at risk of disease recurrence. The primary endpoints of the study are safety and immunogenicity. Details of the Phase I trial can be found at http://clinicaltrials.gov. TapImmune is sponsoring the Phase I study and has an Exclusive Option to Li
